Cerus (NASDAQ:CERS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, January 30th.
According to Zacks, “Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company’s initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. “
Other equities analysts also recently issued research reports about the company. BTIG Research reiterated a “neutral” rating on shares of Cerus in a report on Friday, December 8th. ValuEngine upgraded Cerus from a “strong sell” rating to a “sell” rating in a report on Thursday, January 4th. BidaskClub upgraded Cerus from a “strong sell” rating to a “sell” rating in a report on Friday, January 5th. Cantor Fitzgerald restated an “overweight” rating and set a $5.00 price target on shares of Cerus in a report on Friday, January 5th. Finally, Cowen set a $6.00 price target on Cerus and gave the company a “buy” rating in a report on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $5.83.
Cerus (CERS) opened at $4.12 on Tuesday. The company has a quick ratio of 3.11, a current ratio of 3.71 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $476.09, a price-to-earnings ratio of -6.98 and a beta of 2.22. Cerus has a twelve month low of $1.93 and a twelve month high of $5.43.
Large investors have recently made changes to their positions in the business. BB&T Securities LLC purchased a new position in Cerus in the third quarter worth about $100,000. Teacher Retirement System of Texas purchased a new position in Cerus in the fourth quarter worth about $126,000. UBS Asset Management Americas Inc. boosted its position in Cerus by 59.3% in the second quarter. UBS Asset Management Americas Inc. now owns 48,377 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 18,000 shares during the last quarter. MetLife Investment Advisors LLC purchased a new position in Cerus in the fourth quarter worth about $197,000. Finally, Voya Investment Management LLC boosted its position in Cerus by 22.0% in the second quarter. Voya Investment Management LLC now owns 58,633 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 10,570 shares during the last quarter. 51.52% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Cerus (NASDAQ:CERS) Downgraded to Sell at Zacks Investment Research” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/16/cerus-cers-stock-rating-lowered-by-zacks-investment-research.html.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Get a free copy of the Zacks research report on Cerus (CERS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.